DK1653943T4 - Catecholderivater til behandling af cancer - Google Patents
Catecholderivater til behandling af cancerInfo
- Publication number
- DK1653943T4 DK1653943T4 DK04777151T DK04777151T DK1653943T4 DK 1653943 T4 DK1653943 T4 DK 1653943T4 DK 04777151 T DK04777151 T DK 04777151T DK 04777151 T DK04777151 T DK 04777151T DK 1653943 T4 DK1653943 T4 DK 1653943T4
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- medicament
- cancer
- treatment
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48288603P | 2003-06-25 | 2003-06-25 | |
| PCT/US2004/020569 WO2005009434A2 (en) | 2003-06-25 | 2004-06-25 | Compounds and methods for inducing apoptosis in cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1653943T3 DK1653943T3 (da) | 2008-06-23 |
| DK1653943T4 true DK1653943T4 (da) | 2008-12-01 |
Family
ID=34102647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04777151T DK1653943T4 (da) | 2003-06-25 | 2004-06-25 | Catecholderivater til behandling af cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7812058B2 (pl) |
| EP (2) | EP1653943B3 (pl) |
| JP (2) | JP2007524633A (pl) |
| AT (2) | ATE478663T1 (pl) |
| AU (1) | AU2004258867B2 (pl) |
| CA (1) | CA2529507C (pl) |
| DE (2) | DE602004012279T3 (pl) |
| DK (1) | DK1653943T4 (pl) |
| ES (2) | ES2303096T7 (pl) |
| PL (1) | PL1653943T6 (pl) |
| PT (1) | PT1653943E (pl) |
| SI (1) | SI1653943T1 (pl) |
| WO (1) | WO2005009434A2 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| WO2003038060A2 (en) * | 2001-11-01 | 2003-05-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
| EP1653943B3 (en) | 2003-06-25 | 2008-07-30 | The Burnham Institute | Catechol derivatives for the treatment of cancer |
| CN1960719B (zh) | 2004-03-25 | 2011-12-07 | 密执安州立大学董事会 | 棉酚共结晶及其应用 |
| US20060144723A1 (en) * | 2004-11-02 | 2006-07-06 | Mary Fuller | Device for securing valuables |
| JP5406194B2 (ja) * | 2007-10-01 | 2014-02-05 | アセンタ セラピューティックス インコーポレイティッド | R−ゴシポールl−フェニルアラニノールジエナミンを調製するための方法 |
| AU2008311827A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| FR2924712B1 (fr) | 2007-12-06 | 2012-12-21 | Univ Maine | Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications |
| GB0725077D0 (en) * | 2007-12-21 | 2008-01-30 | Univ Murcia | Antifolate com[ounds for the treatment of melanoma |
| WO2009126172A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
| US20110144125A1 (en) * | 2008-08-14 | 2011-06-16 | The Uab Research Foundation | Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore |
| AU2010236416A1 (en) | 2009-04-15 | 2011-11-03 | Sanford-Burnham Medical Research Institute | Naphthalene-based inhibitors of anti-apoptotic proteins |
| US8487131B2 (en) | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8772264B2 (en) | 2009-08-04 | 2014-07-08 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| BR112012009388A2 (pt) | 2009-10-08 | 2016-06-14 | Sanford Burnham Med Res Inst | derivados de apogossipolone como agentes anticâncer |
| EP2956470A4 (en) * | 2013-02-15 | 2016-12-07 | Univ Michigan Regents | COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS |
| US9655998B2 (en) | 2014-08-07 | 2017-05-23 | Cook Medical Technologies Llc | Encapsulated drug compositions and methods of use thereof |
| US9180226B1 (en) | 2014-08-07 | 2015-11-10 | Cook Medical Technologies Llc | Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof |
| US11241520B2 (en) | 2014-08-07 | 2022-02-08 | Cook Medical Technologies Llc | Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2016149675A1 (en) * | 2015-03-19 | 2016-09-22 | Epstein Wendy Anne | Compounds and forms of treatment for female sexual disorders |
| RU2654711C1 (ru) * | 2017-07-10 | 2018-05-22 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, обладающее апоптоз-индуцирующей активностью |
| EP3780986B1 (en) * | 2018-04-20 | 2023-06-21 | NIKE Innovate C.V. | Sole structure with plates and intervening fluid-filled bladder |
| CN110128290B (zh) * | 2019-05-10 | 2022-04-29 | 江苏耐雀生物工程技术有限公司 | 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用 |
| CA3155694A1 (en) * | 2019-09-24 | 2021-04-01 | Genetec Inc. | Intermediary device for daisy chain and tree configuration in hybrid data/power connection |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5385936A (en) * | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
| US5804567A (en) * | 1996-07-18 | 1998-09-08 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method of increasing the effectiveness of anti-metabolites |
| JPH1036260A (ja) * | 1996-07-18 | 1998-02-10 | Mitsui Norin Kk | 抗ガン剤の効力増強方法 |
| US6428818B1 (en) | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
| CN100490791C (zh) * | 2000-12-15 | 2009-05-27 | 维克沃姆有限公司 | 治疗与新血管生成相关疾病的组合物及方法 |
| SG157952A1 (en) * | 2001-05-30 | 2010-01-29 | Univ Michigan | Small molecule antagonists of bcl-2 family proteins |
| US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| EP1653943B3 (en) * | 2003-06-25 | 2008-07-30 | The Burnham Institute | Catechol derivatives for the treatment of cancer |
-
2004
- 2004-06-25 EP EP04777151A patent/EP1653943B3/en not_active Expired - Lifetime
- 2004-06-25 JP JP2006517702A patent/JP2007524633A/ja active Pending
- 2004-06-25 AT AT08003839T patent/ATE478663T1/de not_active IP Right Cessation
- 2004-06-25 DE DE602004012279T patent/DE602004012279T3/de not_active Expired - Lifetime
- 2004-06-25 CA CA2529507A patent/CA2529507C/en not_active Expired - Fee Related
- 2004-06-25 US US10/877,781 patent/US7812058B2/en not_active Expired - Fee Related
- 2004-06-25 ES ES04777151T patent/ES2303096T7/es active Active
- 2004-06-25 WO PCT/US2004/020569 patent/WO2005009434A2/en not_active Ceased
- 2004-06-25 ES ES08003839T patent/ES2351581T3/es not_active Expired - Lifetime
- 2004-06-25 PL PL04777151T patent/PL1653943T6/pl unknown
- 2004-06-25 DK DK04777151T patent/DK1653943T4/da active
- 2004-06-25 EP EP08003839A patent/EP1938816B1/en not_active Expired - Lifetime
- 2004-06-25 AT AT04777151T patent/ATE387911T1/de not_active IP Right Cessation
- 2004-06-25 AU AU2004258867A patent/AU2004258867B2/en not_active Ceased
- 2004-06-25 DE DE602004028880T patent/DE602004028880D1/de not_active Expired - Lifetime
- 2004-06-25 SI SI200430628T patent/SI1653943T1/sl unknown
- 2004-06-25 PT PT04777151T patent/PT1653943E/pt unknown
-
2010
- 2010-10-07 US US12/900,319 patent/US8367644B2/en not_active Expired - Fee Related
-
2011
- 2011-09-29 JP JP2011215077A patent/JP2012025767A/ja active Pending
- 2011-12-19 US US13/329,611 patent/US20120269901A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1653943T3 (da) | Catecholderivater til behandling af cancer | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| NZ543897A (en) | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| GB0318447D0 (en) | Therapeutic agents | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| AR050045A1 (es) | Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| WO2008009210A8 (fr) | Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses | |
| DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
| UA93673C2 (ru) | Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| TW200510384A (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| WO2002074756A3 (de) | Urokinase-inhibitoren | |
| MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
| ECSP078015A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis | |
| RU2004103625A (ru) | Новые производные мандальной кислоты и их применение в качестве ингибиторов тромбина | |
| TW200640464A (en) | Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient | |
| WO2006007508A3 (en) | Compounds and methods for treating diabetic vascular diseases |